Business
Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)
Levosimendan was shown to Reduce Stressed Blood Volume (SBV), a Novel and Highly Relevant Mechanism of Action for PH-HFpEF Patients Stressed Blood Volume
About this update from Tenax Therapeutics, Inc.
[{"type":"text","content":"\n\nLevosimendan was shown to Reduce Stressed Blood Volume (SBV), a Novel and Highly Relevant Mechanism of Action for PH-HFpEF Patients \n\n\nStressed Blood Volume Reductions Accompany Previously Reported Improvements in Important Cardiovascular Hemodynamic Measurements \n\n\nReduction in Stressed Blood Volume Suggests the Effects of Levosimendan are Modulated Through K-ATP Channel Activation and Resulting Venodilation \n\n\n MORRISVILLE, N.C.--(BUSINESS WIRE)--\nTenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardiopulmonary diseases with a high unmet medical need, today announced a new publication that identifies a novel mechanism of action behind the improved cardiovascular hemodynamics and exercise tolerance that was reported in the recent Phase 2 HELP Study (Burkhoff et al., JACC Heart Failure 2021; 9:360-70). The HELP Study evaluated levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The new publication, “Changes in Stressed Blood Volume with Levosimendan in Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction: Insights Regarding Mechanism of Action” appears in the Journal of Cardiac Failure. The article is available online as an “Article In Press”. https://www.onlinejcf.com/article/S1071-9164(21)00215-3/fulltext\n\nThe authors conducted an in-depth analysis of data from the HELP Study to elucidate the underlying mechanism behind the improved hemodynamic and exercise capacity effects seen in levosimendan-treated patients. Their analysis found that the reductions in pulmonary wedge pressure (PCWP) and central venous pressure (CVP) were independent of any inotropic effect of the drug. Instead, the authors conclude that the reduction in PCWP and CVP shown in the HELP Study was attributable to levosimendan’s ability to lower stressed blood volume (SBV) through its effect on K+ATP channel activation. The splanchnic circulation is composed of the blood that supplies all of the abdominal viscera, and serves as a reservoir to increase or decrease venous return (referred to as stressed blood volume) to the heart as dictated by physiologic conditions. It has been validated that dilating the splanchnic circulation will lower SBV and hence CVP and PCWP in PH-...